Third International Stroke Trial "IST-3"

Completed

Phase 3 Results

Summary of Purpose

To determine whether administration of recombinant tissue plasminogen activator (r-tPA) within 6 hours of ischemic stroke increases the proportion of independent survivors at 6 months.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 2 March 2010.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • UK Medical Research Council, the Health Foundation, the Stroke Association (UK), the Norwegian Research Council, the Government of Poland, AFA insurances (Sweden), and the Australian Heart Foundation.

Trial Design

International, multicenter, prospective, randomized, open, blinded endpoint (PROBE) design controlled trial.

Contacts

  • Karen Innes IST-3 Neurosciences Trials Unit University of Edinburgh Bramwell Dott Building Western General Hospital Edinburgh, EH4 2XU Scotland Email: IST3@skull.dcn.ed.ac.uk

    Peter.sandercock@ed.ac.uk